You are here: Industry Insights > Athenex

News List

Gland Pharma launches of the first non-frozen ready-to-use Bivalirudin expresspharma
June 09, 2020
Bivalirudin RTU Injection is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention.
SunGen Pharma, Athenex Pharma Partner for Bivalirudin Launch contractpharma
June 28, 2019
An anticoagulant injection with 2018 US Market Sales at $81.8M according to IQVIA data.
SunGen Pharma and Athenex Pharmaceutical Division Announce Busulfan Injection Product Launch pharmafocusasia
March 14, 2019
SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced the launch of Busulfan Injection...
Athenex Announces License Agreement with PharmaEssentia for Oradoxel (Oral Formulation of Docetaxel) in Several Areas in Asia pharmafocusasia
December 03, 2018
Athenex, Inc., a global biopharmaceutical company dedicated to the research of new therapies for cancer and related diseases, Development and commercialization......
Two Athenex phase 3 trials show 100% skin clearance of precancerous lesions fiercebiotech
July 30, 2018
Athenex reported that two phase 3 trials of its skin ointment for precancerous lesions saw 100% clearance of actinic keratosis growths within 60 days, including in the face and scalp.
Athenex Names Timothy Cook as Senior Vice President of Global Commercial Oncology firstwordpharma
July 10, 2018
thenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Timothy Cook as Senior V
Athenex rakes in $100M, sets up Chinese TCR-focused JV fiercebiotech
July 09, 2018
Just over a year since its IPO, Athenex is broadening its scope—the biotech is picking up a $100 million investment from Perceptive Advisors, licensing a modified cancer-fighting enzyme and launching a new Chinese joint venture built around T-cell recepto
Athenex announces joint venture with Xiangxue Life Sciences biospectrumasia
July 04, 2018
Apart from this, Athenex has also announced in-licensing of worldwide rights to a pegylated genetically modified human arginase from Avalon PolyTom (HK) Limited (PolyTom)
Athenex announces the promotion of Jeffrey M. Yordon pharmaasia
April 01, 2017
Athenex, announced the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer (COO) for the company effective upon Board approval.
Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Com en-cphi.cn
March 29, 2017
Athenex, Inc.announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed into human clinical trials with the combination of oral topotecan and its proprietary P-glycoprotein (P-gp) inhibitor HM30181A.

Previous page 1 2 Next page